ABL Bio Inc

ABL Bio Inc. is a biotechnology research company focused on developing therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline includes ABL301, in Phase 1 for Parkinson's disease; ABL503 and ABL111, in Phase 1 for solid tumors; ABL102 for solid and blood tumors; ABL103 for solid cancers; ABL104 for solid tumors; and ABL105, in Phase 1 for solid tumors. The company was incorporated in 2016 and is based in Seoul, South Korea.